Epigenetic Modulation for Cancer Therapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 106
Special Issue Editor
Special Issue Information
Dear Colleagues,
Epigenetic modulation for cancer therapy is an emerging and promising approach in the field of oncology. Heritable changes in gene expression that occur without any changes to the DNA sequence are called epigenetics. In cancer, genes that promote tumor growth, invasion, and metastasis may be expressed aberrantly due to epigenetic modifications. Cancer therapy has become more attractive by targeting epigenetic changes. The aim of this Special Issue is to provide a platform on which to share cutting-edge discoveries, novel strategies, and therapeutic approaches that target epigenetic modifications in cancer. Submissions can cover a range of topics, including, but not limited to, the following:
- DNA methylation inhibitors used for the treatment of cancer.
- Histone-modification-targeted therapies to treat various cancer types.
- Non-coding RNAs as epigenetic regulators in cancer.
- Epigenetic biomarkers in the diagnosis and prognosis of cancer.
- Epigenetic-based combination therapies.
- Mechanisms involved in epigenetic dysregulation in diverse cancer subtypes.
- Potential of epigenetic editing for precision cancer medicine.
Both basic and clinical research perspectives are encouraged to contribute. Authors are invited to share their insights, discoveries, and innovations in epigenetic modulation for cancer therapy.
Dr. Zheng-Yuan Su
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- cancer therapy
- DNA methylation
- histone modifications
- non-coding RNAs
- precision medicine
- biomarkers
